1. Academic Validation
  2. Discovery of De Novo Macrocycle Inhibitors of Histone Deacetylase 11

Discovery of De Novo Macrocycle Inhibitors of Histone Deacetylase 11

  • JACS Au. 2025 Feb 16;5(3):1299-1307. doi: 10.1021/jacsau.4c01148.
Daniela Danková 1 Alexander L Nielsen 2 Anne Zarda 2 Tobias N Hansen 1 Marie Hesse 1 Michaela Benová 1 Athanasios Tsiris 1 Christian R O Bartling 1 Edward J Will 2 Kristian Strømgaard 1 Carlos Moreno-Yruela 1 2 Christian Heinis 2 Christian A Olsen 1
Affiliations

Affiliations

  • 1 Center for Biopharmaceuticals and Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Jagtvej 160, DK-2100 Copenhagen, Denmark.
  • 2 Institute of Chemical Sciences and Engineering, School of Basic Sciences, École Polytechnique Fédérale de Lausanne (EPFL), CH-1015 Lausanne, Switzerland.
Abstract

Histone deacetylase (HDAC) Enzymes are epigenetic regulators that affect diverse protein function by removing acyl groups from lysine side chains throughout the proteome. The most recently discovered human isozyme, HDAC11, differs from Other HDACs in substrate preference and tissue expression profile. Elucidation of the biological function of this enzyme has been scarce and only a few chemical probes to help advance this insight have been developed thus far. Here we discovered macrocyclic inhibitors that exhibit selectivity for HDAC11 and penetrate the cytoplasmic membrane in cultured cells as determined by the chloroalkane penetration assay. Our work establishes the combination of de novo macrocycle synthesis with incorporation of N-alkylated hydroxamic acid moieties as a viable strategy for targeting HDAC11. Further, this study demonstrates the potential of applying macrocyclic peptide-based library synthesis to directly furnish high-affinity, cell-permeating ligands. The discovered inhibitors comprise tool compounds for the investigation of the biological function of HDAC11.

Figures
Products